bio sketch column
Dr. Kleiman has contributed to the discovery and development of multiple novel clinical candidates and has worked at companies that span the big pharma, start-up and biotech industries. Her background includes leading discovery programs, overseeing external collaborations, consulting, and management experience at several biotech companies and Pfizer. She was one of several founding members of the Pfizer Neuroscience Phosphodiesterase platform team that produced multiple clinical candidate molecules, three first-in-human clinical trials for distinct and completely novel mechanisms followed by two proof-of-concept clinical trials. She led an interdisciplinary effort to use human risk gene biology to develop a strategy for new target identification and validation that will yield novel therapeutics to treat psychiatric disorders. Dr. Kleiman joined the Translational Neuroscience Center (TNC) leadership team and faculty at Boston’s Children’s Hospital in August of 2013 as the head of preclinical research to provide drug discovery expertise to the members of the TNC community, develop a robust portfolio of translational research projects and foster more in-depth collaboration with industry and disease-based foundations to develop novel therapies to improve the lives of pediatric and adolescent patients.